Preclinical Activity of Two Paclitaxel Nanoparticle Formulations After Intraperitoneal Administration in Ovarian Cancer Murine Xenografts
Jesse Demuytere,Charlotte Carlier,Leen Van de Sande,Anne Hoorens,Kaat De Clercq,Silvia Giordano,Lavinia Morosi,Cristina Matteo,Massimo Zucchetti,Enrico Davoli,Jo Van Dorpe,Chris Vervaet,Wim Ceelen
DOI: https://doi.org/10.2147/ijn.s424045
IF: 7.033
2024-01-17
International Journal of Nanomedicine
Abstract:Jesse Demuytere, 1, &ast Charlotte Carlier, 1, &ast Leen Van de Sande, 1 Anne Hoorens, 2 Kaat De Clercq, 3 Silvia Giordano, 4 Lavinia Morosi, 4 Cristina Matteo, 4 Massimo Zucchetti, 4 Enrico Davoli, 4 Jo Van Dorpe, 2 Chris Vervaet, 3 Wim Ceelen 1 1 Department of GI Surgery, Ghent University Hospital, and Cancer Research Institute Ghent (CRIG), Ghent, Belgium; 2 Department of Pathology, Ghent University Hospital, Ghent, Belgium; 3 Laboratory of Pharmaceutical Technology, Ghent University, Ghent, Belgium; 4 Department of Environmental Health Sciences, Istituto di Ricerche Farmacologiche Mario Negri - IRCCS, Milano, Italy &astThese authors contributed equally to this work Correspondence: Wim Ceelen, Department of GI Surgery, Ghent University Hospital, Route 1275, Corneel Heymanslaan 10, Ghent, B-9000, Belgium, Tel +32 9 332 6251, Email Background: Epithelial ovarian cancer is associated with high mortality due to diagnosis at later stages associated with peritoneal involvement. Several trials have evaluated the effect of intraperitoneal treatment. In this preclinical study, we report the efficacy, pharmacokinetics and pharmacodynamics of intraperitoneal treatment with two approved nanomolecular formulations of paclitaxel (nab-PTX and mic-PTX) in a murine ovarian cancer xenograft model. Methods: IC50 was determined in vitro on three ovarian cancer cell lines (OVCAR-3, SK-OV-3 and SK-OV-3-Luc IP1). EOC xenografts were achieved using a modified subperitoneal implantation technique. Drug treatment was initiated 2 weeks after engraftment, and tumor volume and survival were assessed. Pharmacokinetics and drug distribution effects were assessed using UHPLC-MS/MS and MALDI imaging mass spectrometry, respectively. Pharmacodynamic effects were analyzed using immunohistochemistry and transmission electron microscopy using standard protocols. Results: We demonstrated sub-micromolar IC 50 concentrations for both formulations on three EOC cancer cell lines in vitro. Furthermore, IP administration of nab-PTX or mic-PTX lead to more than 2-fold longer survival compared to a control treatment of IP saline administration (30 days in controls, 66 days in nab-PTX treated animals, and 76 days in mic-PTX animals, respectively). We observed higher tissue uptake of drug following nab-PTX administration when compared to mic-PTX, with highest uptake after 4 hours post-treatment, and confirmed this lower uptake of mic-PTX using HPLC on digested tumor samples. Furthermore, apoptosis was not increased in tumor implants up to 24h post-treatment. Conclusion: Intraperitoneal administration of both nab-PTX and mic-PTX results in a significant anticancer efficacy and survival benefit in a mouse OC xenograft model. Keywords: ovarian, peritoneal, paclitaxel, nanomedicine Epithelial ovarian cancer (EOC) is the 8th most common cause of cancer death worldwide, accounting for an estimate of over 150,000 deaths per year. This particularly high mortality is mainly attributed to diagnosis at an advanced (eg FIGO III or IV) stage, with disease commonly involving the peritoneum. 1,2 Current standard treatment for advanced EOC consists of both complete cytoreductive surgery and systemic paclitaxel and carboplatin-based chemotherapy. 3 Several randomized clinical trials have aimed to evaluate the effect of intraperitoneal (IP) administration of chemotherapy, particularly the platinum component, with positive results. 4,5 However, the future role of IP therapy remains to be established. 6 The peritoneal cavity is ideally situated to allow for locoregional therapies, due to the ease by which it can be accessed. Additionally, the peritoneal-plasma barrier confers a favorable pharmacokinetic profile, including slower clearance, and higher possible local doses of chemotherapeutic drugs. 7 Other potential advantages of IP therapy over systemic therapy include the possibility of an increased capacity to reach small lesions with less-developed vasculature, and lower systemic effects. 8,9 Paclitaxel (PTX), a member of the taxane group, is particularly suited for IP administration on a theoretical basis, due to a described peritoneal/plasma ratio of 1000, and significant hepatic first-pass metabolism. 10 PTX is FDA approved for the systemic treatment of several solid cancers, including ovarian, breast and lung cancer. 11 Due to its high hydrophobicity, it is solubilized in a mixture (1:1) of Cremophor ® EL (CrEl) and dehydrated ethanol, known as solvent-based PTX (sb-PTX).<su -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology